MARKET

STML

STML

Stemline
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.05
-0.15
-1.47%
After Hours: 10.05 0 0.00% 16:00 12/13 EST
OPEN
10.20
PREV CLOSE
10.20
HIGH
10.30
LOW
9.86
VOLUME
254.15K
TURNOVER
--
52 WEEK HIGH
18.22
52 WEEK LOW
7.82
MARKET CAP
502.60M
P/E (TTM)
-4.1611
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of STML and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

STML News

  • Stemline Therapeutics: Post-ASH Update For This Leader In The CD123 Space
  • Seeking Alpha - Article.3d ago
  • Stemline Therapeutics Inc (STML): Hedge Funds Are Snapping Up
  • Insider Monkey.4d ago
  • Stemline Therapeutics Recaps ELZONRIS Clinical Data Presentations in Patients with Myelofibrosis (oral presentation) and Multiple Myeloma at the 61st American Society of Hematology (ASH) Annual Meeting
  • GlobeNewswire.4d ago
  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.12/07 13:35

More

Industry

Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Name
Price
%Change

About STML

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
More

Webull offers Stemline Therapeutics Inc (STML) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.